10-Q: Manhattan Scientifics Reports Net Loss of $540,000 for Six Months Ended June 30, 2024

Manhattan Scientifics, Inc. reported a net loss of $540,000 for the six months ended June 30, 2024, an improvement compared to the $649,000 loss in the same period of 2023.

Summary

• Manhattan Scientifics, Inc. reported its financial results for the second quarter and six months ended June 30, 2024.
• The company's net loss for the six months ended June 30, 2024, was $540,000, compared to a net loss of $649,000 for the same period in 2023.
• There was no revenue recorded during the six months ended June 30, 2024.
• General and administrative expenses decreased to $347,000 from $367,000 year-over-year.
• The company's research and development costs remained consistent at $5,000 for both periods.
• The loss on fair value adjustment of investments improved, resulting in a total other expense of $188,000 compared to $277,000 in the prior year.
• As of June 30, 2024, the company had a stockholders' deficit of $3,400,000 and a working capital deficit of $2,371,000.
• The company's cash and cash equivalents decreased to $38,000 from $67,000 at the beginning of the year.
• Manhattan Scientifics anticipates royalty income as nanotitanium is commercialized for use in medical prosthetics, with royalties of 10% on sales of licensed dental products and an average of 5% on all other sales of licensed products.
• The company needs to raise additional working capital through licensing its technology and generating revenues for other services and may need to engage in equity or debt financing to secure additional funds.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the net loss has decreased, the company still faces significant financial challenges, including a stockholders' deficit and the need for additional financing. The potential for future royalty income is a positive sign, but the company's overall financial stability remains uncertain.

Positives

• The net loss decreased by $109,000 compared to the same period last year, indicating improved financial performance.
• General and administrative expenses decreased, reflecting cost-cutting measures.
• The loss on fair value adjustment of investments decreased, contributing to the reduced net loss.
• The company anticipates royalty income from its ECAP technology.

Negatives

• The company reported a net loss of $540,000 for the six months ended June 30, 2024.
• The company has a stockholders' deficit of $3,400,000 and a working capital deficit of $2,371,000.
• Cash and cash equivalents decreased to $38,000 as of June 30, 2024.
• The company has no revenue recorded during the six months ended June 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on generating cash from the sale of common stock and/or obtaining debt financing and attaining future profitable operations.
• The company may need to engage in equity or debt financing to secure additional funds, which could result in significant dilution for existing stockholders.
• The company may not be able to obtain additional financing on terms favorable to it, if at all.
• The company's success depends on protecting its proprietary technology and operating without infringing on the proprietary rights of others.
• The company relies on certain technology licensed from the Los Alamos National Laboratory and may be required to license additional technologies in the future, which may not be available on acceptable terms.

Future Outlook

The company anticipates royalty income as nanotitanium is commercialized for use in medical prosthetics and plans to raise additional working capital through licensing its technology and generating revenues for other services.

Industry Context

Manhattan Scientifics operates in the technology transfer and commercialization sector, focusing on nanotechnology. The company's performance is influenced by its ability to secure and commercialize emerging technologies, particularly in the medical and dental fields. Competition in this sector is intense, with various entities having greater resources.

Comparison to Industry Standards

• It is difficult to compare Manhattan Scientifics directly to industry standards due to its unique business model as a technology incubator.
• However, similar companies in the nanotechnology sector often rely on research grants, venture capital, and strategic partnerships to fund their operations.
• Companies like Nano-X Imaging and Cytosorbents have achieved commercial success in specific applications of nanotechnology, demonstrating the potential for revenue generation in this field.
• Manhattan Scientifics' reliance on licensing and royalty agreements is a common strategy in the technology transfer industry, but its success depends on the commercial viability of its licensed technologies.

Related Party Transactions

• As of June 30, 2024, the company had accrued expenses to related parties of approximately $2,180,000.
• The amounts are due to the company's sole officer for compensation $616,000 and the chairman of the board for compensation of $1,461,000 and the members of the board of directors of $102,000.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional equity.
• Employees' job security is dependent on the company's ability to secure additional financing and generate revenue.
• The company's ability to commercialize its technologies could impact customers in the medical and dental fields.
• The company's suppliers and creditors are at risk if the company is unable to meet its financial obligations.

Next Steps

• The company intends to raise additional working capital through the continued licensing of its technology.
• The company intends to generate revenues for other services.
• The company may need to engage in equity or debt financing to secure additional funds.

Key Dates

Keywords

financial results, nanotechnology, ECAP technology, Imagion, Metallicum, Manhattan Scientifics